Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. Spark Ventures, NESTA and Catapult Venture Managers are the major investors. £2.8 million funding has been raised since the company's inception - the latest £1.24 million investment round was completed in 2008. The Haemostatix management team has proven experience in product development and commercialisation and is supported by a recently strengthened board of directors. More...

Haemostatix was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats.

This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery and trauma, and in leukaemic patients.  More...

|	Created by One Vision Ltd